Expanded Data Table 2.

Summary of systemic drug treatments received by each patient

Treatment Received (n=60)	N (%)
Pembrolizumab
2 mg/kg	33 (55%)
10 mg/kg	10 (17%)
Dose not known	2 (3%)
Nivolumab
0.1 mg/kg	2 (3%)
3 mg/kg	5 (8%)
10 mg/kg	1 (2%)
Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg)	3 (5%)
Pembrolizumab (2 mg/kg) + ipilimumab (1 mg/kg)	1 (2%)
BMS-936559 (anti-PDL1)
0.1 mg/kg	1 (2%)
0.3 mg/kg	2 (3%)
Cycles of therapy (median/range)	12 (1–73)
Length of follow-up (median)	22 months
Time to best response (median)	4 months
Duration of response (median)	17 months
Received subsequent systemic therapy	4 (7%)
Received surgical excision for isolated progression	3 (5%)